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Abstract Although previous studies have shown that dopamine 
(DA) antagonists block amphetamine reward, these studies have 
utilized animal models that involve repeated exposures to amphet-
amine. The present investigation examined the effect of DA antag-
onists on single-trial conditioned place preference (CPP) produced 
by acute intravenous (IV) amphetamine in rats. In the fi rst experi-
ment, rats were prepared with a jugular catheter and then received 
an acute IV injection of amphetamine (0.1–3 mg/kg) paired with 
one compartment of a CPP apparatus. Relative to sham controls (no 
IV catheter), amphetamine produced a dose-dependent increase in 
locomotor activity and CPP. Two further experiments demonstrat-
ed that both effects of amphetamine were completely blocked by 
pretreating rats with the D1 DA antagonist SCH-23390 (0.025 and 
0.25 mg/kg) or the D2 DA antagonist eticlopride (0.2 and 2 mg/kg) 
on the conditioning trial. In a fi nal experiment, single-trial amphet-
amine CPP did not predict subsequent self-administration of IV am-
phetamine (10–50 μg/infusion) using either a fi xed ratio (FR) 1 or 
progressive ratio (PR) schedule of reinforcement. Thus, while shar-
ing a similar DA receptor mechanism, the present results indicate 
that single-trial CPP and self-administration are dissociable effects 
of IV amphetamine. 
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Introduction 
Clinical evidence suggests that vulnerability to drug abuse may be 
predicted by the degree of positive reward derived from the initial 
drug experience (Haertzen et al. 1983). Individual differences in the 
acute rewarding effect of various drugs of abuse probably refl ect, at 
least in part, neuropharmacological differences related to both ge-
netic and environmental factors. Unfortunately, investigations into 
the neuropharmacological mechanisms that underlie acute drug re-
ward are lacking. In humans, most studies of drug reward involve 
subjects that have an extensive history of drug-taking. Similarly, 
animal models of drug reward, such as conditioned place prefer-
ence (CPP) or self-administration (Yokel 1987; Carr et al. 1989), 
typically require repeated drug exposures. Since repeated drug ex-
posure may produce either tolerance or sensitization to the behav-
ioral effect of various drugs (Stewart and Badiani 1993; Ramsay 
and Woods 1997; Schenk and Partridge 1997), these approaches do 
not allow for assessment of the neuropharmacological mechanisms 
of acute drug reward. 
One potential strategy to assess acute drug reward in laboratory 
animals is to utilize the single-trial CPP procedure. Although CPP 
typically requires multiple drug conditioning trials, evidence indi-
cates that acute IV injection of a relatively high dose of morphine 
(4–8 mg/kg) induces CPP in rats (Mucha et al. 1982; Bardo and 
Neisewander 1986). This preference is established by rapidly infus-
ing the drug at the beginning of a 30-min placement into a distinct 
stimulus compartment. On the next day, rats are given equivalent 
exposure (without drug) to a different stimulus compartment. When 
rats are subsequently allowed to choose between the two compart-
ments, they show a preference for the drug compartment relative to 
the no-drug compartment. Establishment of this CPP is blocked by 
naloxone (Bardo and Neisewander 1986), indicating that opiate re-
ceptors mediate acute morphine reward. At present, it is unclear if 
single-trial CPP is unique to opiates or whether it may also be ob-
tained with other drug classes. 
The major purpose of the present study was to determine if IV 
amphetamine produces single-trial CPP and to assess if this effect 
is blocked by dopamine (DA) antagonists selective for either the 
D1 receptor family (D1 and D5) or the D2 receptor family (D2, D3 
or D4). Previous work has shown that amphetamine reward is at-
tenuated by either D1 or D2 DA antagonists (Yokel and Wise 1975; 
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Spyraki et al. 1982; Hoffman and Beninger 1989). In all of these 
studies, however, amphetamine reward was assessed with repeat-
ed drug treatment in either a CPP or self-administration model. It 
is well known that repeated amphetamine treatment induces behav-
ioral sensitization and alters activity of the mesolimbic DA system 
(Robinson and Becker 1986; Kalivas et al. 1993; Cador et al. 1995; 
Segal and Kuczenski 1997). Thus, it not clear if the antagonist-in-
duced attenuation in amphetamine reward would also be obtained 
in a non-sensitized animal model. A secondary purpose of the pres-
ent study was to determine if the acute rewarding effect of IV am-
phetamine, assessed by single-trial CPP, predicts subsequent am-
phetamine abuse liability, assessed by repeated self-administration. 
Materials and methods 
Animals 
Adult male Sprague-Dawley rats (200–225 g body weight) were 
obtained from Harlan Industries (Indianapolis, Ind., USA) and were 
caged individually with free access to food and water in the home 
cage. The colony room was controlled for temperature (24°C) and 
relative humidity (45%), with lights on from 0700 to 1900 hours. 
Prior to the start of each experiment, animals were acclimated to 
the colony room for at least 1 week and were handled for 2 days. 
Behavioral testing was conducted during the light phase of the cy-
cle. All procedures were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. 
Surgery 
Animals were anesthetized (100 mg/kg ketamine, 5 mg/kg diaze-
pam, IP) and implanted with a catheter into the jugular vein. In the 
CPP experiments that required only a single injection of amphet-
amine, a polyethylene tube (PE-50) was inserted into the vein and 
exited out the mid-scapular region of the back. A sterile piece of 
stainless steel tubing was used to close the ending. Sham controls 
received the same surgical treatment, but they did not receive the 
catheter insertion. In the self-administration experiments that re-
quired repeated injections of amphetamine, a Silastic tube was in-
serted into the vein and exited out the top of a head mount that was 
affi xed to the top of the skull with dental acrylic and metal screws. 
Daily infusions of heparinized saline and streptokinase (Pharmacia, 
Columbus, Ohio, USA; 250 000 IU, 2 mg/ml heparinized saline, 
0.1 ml/rat per day) were used to maintain patency of the Silastic 
catheter. At the end of each experiment, each animal was injected 
with IV morphine (15 mg/kg) and presence of a rapid cataleptic re-
sponse was used to confi rm catheter patency. 
Apparatus 
For assessment of locomotor activity and CPP, two similar con-
ditioning apparatus were used. Each apparatus had three different 
wooden compartments separated by removable partitions. The two 
end compartments measured 24× 30× 45 cm high, while the mid-
dle compartment was smaller and measured 24× 10× 45 cm high. 
One end compartment had white walls, a wire mesh fl oor, and pine 
bedding beneath the fl oor. The other end compartment had black 
walls, a metal rod fl oor, and cedar bedding beneath the fl oor. The 
middle compartment had gray walls and a solid wood fl oor. The 
solid partitions could be replaced with similar partitions contain-
ing a 10× 10 cm opening, which allowed the animals access to all 
compartments. The apparatus was located in a laboratory room that 
was separate from the colony room and was equipped with a white 
noise generator and audio speaker (ambient background of 70 dB). 
Suspended from the ceiling above the apparatus was a video cam-
era which was used to record the experimental sessions. 
For assessment of amphetamine self-administration, 12 oper-
ant chambers (ENV-001; Med Associates, St Albans, Vt., USA) 
enclosed in a sound attenuating environment were used. Located 
in the bottom center of the front panel in each chamber was a 5× 
4.2 cm opening to a recessed food tray. Two metal response levers 
were located on the front panel, one on each side of the food tray. 
The center of each lever was mounted 7.3 cm from the grid fl oor. A 
28-V cue light, 3 cm in diameter, was centered 6 cm above each le-
ver. Drug infusions were delivered using a syringe pump (Med As-
sociates; PHM-100) and a water-tight swivel that allowed a cath-
eter to be attached from the syringe (10 ml) to the head mount of 
the animal in the operant chamber. A personal computer, using Med 
Associates interface, controlled the experimental sessions and col-
lected data. 
Behavioral procedures 
For CPP, the conditioning procedure was conducted over 2 consec-
utive days. Because preliminary data from our laboratory indicat-
ed that drug-naive animals tend to show a slight preference for the 
black compartment, amphetamine conditioning was established in 
the white compartment. On day 1, animals were placed individually 
into either the white or black compartments (counterbalanced with-
in treatment groups) for 30 min with the solid partitions inserted 
between the compartments. On day 2, animals received equal ex-
posure to the opposite compartment. Conditioned animals were in-
jected IV with amphetamine immediately following placement into 
the white compartment and were injected with saline immediately 
following placement into the black compartment. Control animals 
received either no injection in either compartment (sham control) 
or received saline in both compartments (saline control). To assess 
the effect of antagonist drugs (SCH23390 or eticlopride), the 2-day 
conditioning procedure was similar, except that the antagonist drug 
was administered IV 5 min before placement into the white com-
partment. Locomotor activity in the white compartment was video-
taped and later scored by an observer who was unaware of each an-
imal’s individual treatment. Locomotor activity was quantifi ed by 
counting the number of times that each animal crossed over a line 
drawn on the video monitor screen that bisected the white compart-
ment in the plane parallel to the end wall. A line cross was opera-
tionally defi ned as both front shoulders crossing the line. 
On the day following the 2-day conditioning procedure, each an-
imal was tested for CPP. The rat was placed into the center gray 
compartment and allowed to enter all compartments of the appara-
tus for 15 min. Test sessions were videotaped and the duration spent 
in each compartment was determined by an observer who was un-
aware of each animal’s individual treatment. Entry into a compart-
ment was operationally defi ned as having both front shoulders in 
the compartment. 
To assess the potential correlation between single-trial amphet-
amine CPP and amphetamine self-administration, a group of rats 
were run in both behavioral procedures. Rats were fi rst implanted 
with a Silastic jugular catheter exiting through a head mount. Af-
ter 2 days of recovery, each animal was assessed for CPP with a 
single dose of amphetamine (1 mg/kg, IV) as described previous-
ly, except that rats were fi rst given a 15-min preference test prior to 
conditioning to establish the baseline preference for each compart-
ment. A baseline preference test was used in this experiment in or-
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der to obtain a measure of amphetamine CPP from all rats in the 
sample, i.e., no rats were assigned to a saline control group. Fol-
lowing baseline testing, amphetamine was subsequently paired 
with the non-preferred compartment and saline was paired with 
the preferred compartment. Following this conditioning procedure, 
rats were again tested for place preference. The magnitude of am-
phetamine CPP for each individual rat was expressed as a percent 
change in duration spent in the non-preferred compartment from 
the preconditioning test to the post-conditioning test. 
On the day following the single-trial CPP test, daily amphet-
amine self-administration sessions (3 h/session) were initiated. Rats 
were fi rst trained to self-administer amphetamine (30 μg/infusion, 
0.1 ml/infusion, 10 s infusion) on a fi xed ratio (FR) 1 schedule us-
ing a two-lever choice procedure. Depression of one lever deliv-
ered amphetamine and depression of the other lever led to no rein-
forcement; the levers were counterbalanced for drug reinforcement 
across rats. Training continued until stable responding on the FR1 
was established. Stable responding was defi ned as 15% or less vari-
ability in the number of responses on the drug lever across three 
consecutive sessions. After this criterion was reached, each rat was 
tested for self-administration of the training dose of amphetamine 
(30 μg/infusion) on a progressive ratio (PR) schedule of drug re-
inforcement across three consecutive sessions (5 h/session). With-
in each PR session, the number of responses required to obtain an 
amphetamine infusion increased incrementally (1, 2, 4, 6, 9, 12, 
15, 20, etc.; see Roberts and Richardson 1992). The last ratio value 
completed for amphetamine infusion within each session was de-
fi ned as the breakpoint. After the breakpoint value was determined 
using 30 μg amphetamine, rats were tested with two other amphet-
amine doses (10 and 50 μg/infusion) across consecutive daily ses-
sions. For each dose, rats were fi rst stabilized on an FR1 schedule 
and then were tested for PR responding as described previously. 
Drugs 
Amphetamine sulfate and morphine sulfate were obtained from the 
National Institute on Drug Abuse (Rockville, Md., USA); R(+)-
SCH-23390 hydrochloride and S(–)-eticlopride hydrochloride 
were purchased from Research Biochemicals International (Natick, 
Mass., USA); ketamine hydrochloride (100 mg/ml injectable) was 
purchased from Fort Dodge Laboratories (Fort Dodge, Iowa, USA); 
and diazepam (5 mg/ml injectable) was purchased from Steris Lab-
oratories (Phoenix, Ariz., USA). For CPP, drugs were prepared in 
sterile heparinized saline (0.9% NaCl) and injected IV in a volume 
of 1 ml/kg body weight. For self-administration, amphetamine was 
prepared in sterile saline and injected IV in a volume of 0.1 ml/in-
fusion. All dosages were calculated using the salt form of the drug. 
Statistics 
In all of the single-trial CPP experiments, locomotor activity and 
preference data were analyzed by separate factorial analyses of 
variance (ANOVAs). Pairwise comparisons among treatment 
groups were performed using Tukey’s HSD test (Kirk 1968). In 
these analyses, CPP data were expressed as either an absolute mea-
sure of preference (total duration in white compartment) or a rel-
ative measure of preference (total duration in white compartment 
divided by total duration in white+black compartments). Howev-
er, since these two measures yielded essentially equivalent results 
across experiments, only the absolute preference data are present-
ed in graphic form. 
To determine if individual differences in amphetamine CPP pre-
dicted subsequent amphetamine self-administration, a CPP score 
was derived for each animal by subtracting the duration spent in the 
non-preferred compartment prior to conditioning from the duration 
spent in the non-preferred compartment after conditioning. Pear-
son product-moment correlation coeffi cients were then derived by 
correlating the shift in preference with the number of infusions on 
the FR1 and PR schedules. Separate correlation coeffi cients were 
determined for each self-administration test dose of amphetamine 
(10, 30 and 50 μg/infusion). 
Results 
Amphetamine dose-effect curves 
Separate groups of rats (n=9–16/group) were conditioned with a 
single dose of amphetamine (0.1, 0.3, 1 or 3 mg/kg) or received 
no injections (sham control). Within this dose range, there was a 
dose-dependent increase in locomotor activity [F(4,46 )=15.80, 
P<0.0001], with an apparent maximal increase at 1 mg/kg amphet-
amine (see Fig. 1A). Pairwise comparisons between groups re-
vealed that, relative to the sham control, there was a signifi cant in-
crease in activity following 0.3, 1 and 3 mg/kg amphetamine, but 
not following 0.1 mg/kg amphetamine. 
As shown in Fig. 1B, there was also a signifi cant dose-depen-
dent CPP with amphetamine [F(4,48)=11.46, P<0.0001]. Pairwise 
comparisons between groups revealed that, relative to the sham 
control, there was a signifi cant increase in preference following 1
Fig. 1A, B Dose-effect curves for locomotor activity and CPP with 
acute IV amphetamine. A Mean level of activity (±SEM) measured 
in the white compartment immediately following amphetamine or 
sham injection. B Duration of time spent in the drug-paired white 
compartment on the test day following single-trial amphetamine 
conditioning. In both panels, an asterisk (*) represents a signifi cant 
difference from the sham control group and a hash (#) represents 
a signifi cant difference from 1 mg/kg amphetamine group [Tukey’s 
test, P<0.05] 
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Fig. 2A–D Effect of varying doses of SCH-23390 or eticlopride on lo-
comotor activity and CPP produced by acute IV amphetamine (1 mg/
kg). A Mean level of activity (±SEM) on the conditioning day in rats 
pretreated with SCH-23390 or saline and then placed in the white com-
partment following either amphetamine (hatched columns) or saline 
(clear columns). B Mean level of activity (±SEM) on the conditioning 
day in rats pretreated with eticlopride or saline and then placed in the 
white compartment following either amphetamine or saline. C Dura-
tion of time spent in the drug-paired compartment on the test day in 
rats previously pretreated with SCH-23390 or saline on the condition-
ing day with amphetamine or saline. D Duration of time spent in the 
drug-paired compartment on the test day in rats previously pretreated 
with eticlopride or saline on the conditioning day with amphetamine or 
saline. In all panels, an asterisk (*) represents a signifi cant difference 
from the saline conditioned group pretreated with the same dose of an-
tagonist (Tukey’s test, P<0.05) 
and 3 mg/kg amphetamine, but not following either 0.1 or 0.3 mg/
kg amphetamine. There was also a signifi cant difference between 
groups conditioned with either 1 or 3 mg/kg amphetamine. 
Effects of DA antagonists 
To assess the role of DA receptor subtypes in the acute effects of 
IV amphetamine, separate groups of rats (n=8–10/group) were pre-
treated with either the D1 antagonist SCH-23390 (0, 0.0025, 0.025 
or 0.25 mg/kg) or the D2 antagonist eticlopride (0, 0.02, 0.2 or 2 
mg/kg) prior to conditioning with amphetamine (1 mg/kg) or sa-
line. As shown in Fig. 2A, SCH-23390 decreased the locomotor 
stimulant effect of amphetamine. The overall ANOVA for locomo-
tor activity revealed a signifi cant interaction between conditioning 
drug (amphetamine or saline) and pretreatment dose of SCH-23390 
[F(7,76)= 10.71, P<0.0001]. In saline-pretreated animals, amphet-
amine produced a signifi cant increase in activity. This amphet-
amine-induced increase was not signifi cantly altered by the low-
est dose of SCH-23390 (0.0025 mg/kg). Pretreatment with 0.025 
mg/kg SCH-23390 blocked the locomotor stimulant effect of am-
phetamine; this dose of SCH-23390 did not signifi cantly decrease 
activity in saline controls. At the highest pretreatment dose of 
SCH23390 (0.25 mg/kg), locomotor activity was almost complete-
ly depressed in both amphetamine and saline conditioned groups. 
As shown in Fig. 2C, SCH-23390 also blocked amphetamine 
CPP. The overall ANOVA for CPP revealed a signifi cant interaction 
between conditioning drug (amphetamine or saline) and pretreat-
ment dose of SCH23390 [F(7,76)=44.45, P<0.0001]. With saline 
pretreatment, amphetamine conditioned animals showed a prefer-
ence for the drug-paired compartment relative to saline controls. 
This amphetamine CPP was not signifi cantly altered by the lowest 
dose of SCH-23390 (0.0025 mg/kg). Pretreatment with either 0.025 
or 0.25 mg/kg SCH-23390 blocked the amphetamine CPP. Pretreat-
ment with SCH-23390 alone (open bars in Fig. 2C) also tended to 
increase preference; however, none of the SCH23390 alone groups 
differed signifi cantly from saline control. 
Similar to SCH-23390, pretreatment with eticlopride decreased 
the locomotor stimulant effect of amphetamine (see Fig. 2B). The 
overall ANOVA revealed a signifi cant interaction between condi-
tioning drug (amphetamine or saline) and pretreatment dose of et-
iclopride [F(7,77)=42.67, P<0.0001]. In saline pretreated animals, 
amphetamine produced a marked increase in activity. This amphet-
amine-induced increase was blocked by the lowest dose of eticlo-
pride (0.02 mg/kg). Higher pretreatment doses of eticlopride (0.2 
and 2 mg/kg) also blocked the locomotor stimulant effect of am-
phetamine. Although the high eticlopride doses also decreased ac-
tivity in saline controls, these differences did not reach statistical 
signifi cance. 
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Fig. 3A, B Dose-effect curves for IV amphetamine self-adminis-
tration using either an FR1 A or PR B schedule of reinforcement. 
The mean PR breakpoint values corresponding to the amphetamine 
doses of 10, 30 and 50 g/infusion were 9, 28.5 and 60, respectively. 
Signifi cant dose-dependent differences in the number of infusions 
were obtained on both the FR1 and PR schedules (Ftest, P<0.05) 
As shown in Fig. 2D, eticlopride blocked amphetamine CPP. 
The overall ANOVA revealed a signifi cant interaction between con-
ditioning drug (amphetamine or saline) and pretreatment dose of 
eticlopride [F(7,77)= 7.33, P<0.0001]. With saline pretreatment, 
amphetamine-conditioned animals showed a preference for the 
drug-paired compartment relative to saline controls. Amphetamine 
CPP was also evident in animals pretreated with 0.02 mg/kg eticlo-
pride, but not in animals pretreated with either 0.2 or 2 mg/kg eti-
clopride. Pretreatment with either 0.2 or 2 mg/kg eticlopride alone 
(open bars in Fig. 2D) produced a signifi cant increase in preference 
compared to saline control. 
Individual differences in amphetamine CPP 
and self-administration 
Individual differences in single-trial amphetamine CPP and am-
phetamine self-administration were correlated in a group of rats 
(n=17) that were assessed in both behavioral procedures as de-
scribed previously. Examination of the CPP group data revealed 
that the shift in preference for the non-preferred compartment af-
ter conditioning ranged from –81 to 290 s, with an average shift 
Fig. 4A, B Relationship between single-trial CPP using IV amphet-
amine (1 mg/kg) and self-administration of IV amphetamine (30 g/
infusion). A Scatterplot of individual data points and a best-fi t line 
derived from rats tested for amphetamine CPP and self-administra-
tion on a FR1 schedule. B Scatterplot of individual data points and 
a best-fi t line derived from rats tested for amphetamine CPP and 
self-administration on a PR schedule. In both panels, the degree of 
relationship was not signifi cant (Pearson r, P>0.05) 
of 99.3 s (data not shown); this within-subject preference shift was 
statistically signifi cant [F(1,16)=19.22, P<0.001]. Examination of 
the self-administration group data, displayed in Figs. 3A and B, 
revealed that the number of infusions varied as a function of am-
phetamine dose on the FR1 schedule [F(2,10)=118.62, P<0.0001] 
and the PR schedule [F(2,10)=7.87, P<0.01]. There was no signif-
icant relationship between amphetamine CPP and number of am-
phetamine infusions at any dose on either the FR1 or PR schedule. 
Scatterplots of the data from the training dose of amphetamine (30 
μg/infusion) are presented in Figs. 4A and B. 
Discussion 
Previous work has demonstrated that single-trial CPP is obtained 
following acute IV morphine (Mucha et al. 1982; Bardo and Neis-
ewander 1986). The present results indicate that single-trial CPP 
is not specifi c to opiate drugs, but that it is also evident following 
acute IV amphetamine. The amphetamine dose-effect curve for sin-
gle-trial CPP was graded within the dose range tested (0.1–3 mg/
kg). Within a similar dose range, other studies have shown that the 
dose-effect curve for multiple-trial CPP following IP or SC injec-
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tions of amphetamine is also graded (Bardo et al. 1995). These re-
sults counter the argument that CPP as a measure of drug reward is 
relatively insensitive to drug dosage (Wise 1989). Despite the grad-
ed effect, however, it should be noted that a plateau in the dose-ef-
fect curve defi ning the maximal conditioning effect was not appar-
ent in the present study. Doses higher than 3 mg/kg amphetamine 
were not tested because of the potential for seizures, as well as evi-
dence indicating that higher doses given repeatedly may produce a 
conditioned place aversion (Bardo et al. 1995). 
In contrast to the present results, at least one report found that 
acute IV cocaine does not induce single-trial CPP (Nomikos and 
Spyraki 1988). While this fi nding suggests that single-trial CPP 
may not generalize to all stimulant drugs, procedural differenc-
es between the cocaine study conducted by Nomikos and Spyraki 
(1988) and the present amphetamine study may account for the dif-
ferential outcomes. First, Nomikos and Spyraki (1988) tested only 
a single dose of cocaine (0.5 mg/kg), whereas the present report 
tested a full range of amphetamine doses (0.1–3 mg/kg). Second, 
Nomikos and Spyraki (1988) injected the rats outside of the condi-
tioning apparatus, whereas the present report injected the rats inside 
of the apparatus. Perhaps having the onset of the IV drug effect in 
the test apparatus, rather than outside the apparatus, led to more ro-
bust conditioning in the present study. This possibility is supported 
by other work showing backward pairing of a conditioned stimulus 
(apparatus compartment) with an unconditioned stimulus (drug ef-
fect), as used in the Nomikos and Spyraki (1988) study, typically 
produces negligible conditioning (Mackintosh 1974). Given these 
procedural differences, it seems premature to conclude that IV co-
caine CPP cannot be obtained with a single trial. Further parametric 
work will be needed to resolve this issue. 
Although there has been some debate in the literature about the 
potential infl uence of conditioned locomotor responses on the ex-
pression of CPP (Swerdlow and Koob 1984; Carr et al. 1989), the 
present results with IV amphetamine show a clear dissociation be-
tween locomotor activity and CPP. Most important, the dose-effect 
curves for amphetamine-induced activity and CPP differed across 
the dose range tested. The lowest dose of amphetamine that in-
creased activity was a half-log unit lower than that needed to pro-
duce CPP. In addition, while a clear plateau in locomotor stimula-
tion was evident at 1 mg/kg amphetamine, no plateau in CPP was 
apparent up to 3 mg/kg amphetamine. These results suggest that, 
although drugs of abuse may increase locomotor activity and pro-
duce reward by activating a similar DA substrate in the brain (Wise 
and Bozarth 1987), expression of these different behaviors also in-
volves some separate neuropharmacological mechanisms. 
The present results also provide evidence about the role of D1 
and D2 DA receptor families on the locomotor stimulant and re-
warding effects of acute IV amphetamine. With locomotor activi-
ty, pretreatment with either SCH-23390 or eticlopride completely 
blocked the locomotor activity induced by IV amphetamine. These 
results are in accord with previous work showing that selective D1 
and D2 DA antagonists are potent blockers of the hyperactivity ob-
served with administration of acute amphetamine via other routes 
(Beninger and Hahn 1983; Mithani et al. 1986; Stewart and Vezi-
na 1987; Vezina and Stewart 1989; Mazurski and Beninger 1991). 
Despite their similar blockade of hyperactivity following acute am-
phetamine, it is important to note that selective D1 and D2 DA an-
tagonists also have a differential effect on the locomotor sensi-
tization obtained with repeated amphetamine injections. That is, 
amphetamine-induced locomotor sensitization is blocked by D1 
antagonists, but not by D2 antagonists (Stewart and Vezina 1987; 
Ujike et al. 1989; Vezina and Stewart 1989; Drew and Glick 1990). 
These fi ndings indicate that locomotor activity following acute am-
phetamine and locomotor sensitization following repeated amphet-
amine injections involves, at least in part, separate neuropharmaco-
logical mechanisms. 
Similar to their effects on amphetamine-induced locomotion, 
SCH-23390 or eticlopride pretreatments blocked completely the 
CPP induced by acute IV amphetamine. These fi ndings are consis-
tent with previous work showing that both D1 and D2 receptors play 
a role in amphetamine reward. In particular, pretreatment with se-
lective D1 or D2 DA antagonists has been shown to attenuate am-
phetamine reward assessed by multiple-trial CPP (Spyraki et al. 
1982; Mithani et al. 1986; Leone and Di Chiara 1987; Hoffman and 
Beninger 1989; Hiroi and White 1991; Acquas and Di Chiara 1994) 
and self-administration (Yokel and Wise 1975; Phillips et al. 1994). 
In these previous studies, however, it is important to note that the 
rewarding effect of amphetamine was assessed across repeated in-
jections. Since the rewarding effect of amphetamine becomes sensi-
tized across repeated administrations (Woolverton et al. 1984; Lett 
1989; Strakowski et al. 1996), it is unclear if the antagonist effects 
observed in these previous studies refl ect either a blockade of the 
acute rewarding effect of amphetamine or a blockade of the sen-
sitization produced by repeated amphetamine injections. The pres-
ent study directly addressed this issue by using a single-trial CPP 
procedure that rules out the contribution of any sensitization that 
occurs with repeated amphetamine injections. Since pretreatment 
with either SCH-23390 or eticlopride blocked single-trial amphet-
amine CPP, these results provide evidence that both D1 and D2 DA 
receptors mediate the primary rewarding effect induced by the fi rst 
amphetamine experience. 
While it seems likely that SCH-23390 and eticlopride disrupted 
single-trial amphetamine CPP by attenuating the acute rewarding 
effect of amphetamine, we cannot rule out the possibility that these 
antagonists may have impaired learning of the CPP behavior inde-
pendent of any direct effect on amphetamine reward. In particular, 
previous work has shown that SCH-23390 may disrupt learning in 
various behavioral tasks across different species (Sanger 1987; Ich-
ihara et al. 1989; Sawaguchi and Goldman-Rakic 1991). Perhaps 
most relevant to the present study, Lin et al. (1994) examined the ef-
fect of SCH-23390 and raclopride on single-trial amphetamine con-
ditioned taste aversion in rats. Like CPP, amphetamine conditioned 
taste aversion is thought to involve the acquisition of a Pavlovian 
association between a conditioned stimulus with amphetamine. In 
the study by Lin et al. (1994), pretreatment with SCH-23390 or ra-
clopride did not alter the conditioned taste aversion produced by 
acute amphetamine. These results indicate that blockade of either 
D1 or D2 DA receptors does not produce a generalized impairment 
in the ability of animals to form a Pavlovian association between 
a conditioned stimulus and amphetamine following a single trial. 
Thus, it seems more likely that the DA antagonists used in the pres-
ent report blocked the acute rewarding effect of amphetamine rath-
er than impairing learning. 
One unexpected fi nding from the present study was that eticlo-
pride alone (no amphetamine) produced a signifi cant preference for 
the drug-paired compartment. A similar trend was observed with 
SCH-23390. However, it is important to note that the DA antago-
nist doses that produced the apparent CPP also abolished activity 
almost completely. This antagonist-induced immobility may have 
prevented habituation to the stimulus compartment on the condi-
tioning day, thus making the compartment relatively more novel on 
the test day. Since rats prefer a novel compartment relative to a fa-
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miliar compartment (Bardo et al. 1989; Parker 1992), the apparent 
antagonist-induced CPP observed here may refl ect a preference for 
novelty. 
In addition to assessing the role of D1 and D2 DA receptors, the 
present study also examined the potential correlation between sin-
gle-trial amphetamine CPP and amphetamine self-administration. 
With human subjects, the degree of self-reported positive reward 
derived from the initial drug experience is related to drug abuse 
vulnerability (Haertzen et al. 1983). To assess this predictive re-
lationship in a controlled setting, individual differences in single-
trial amphetamine CPP were correlated with subsequent rates of 
amphetamine self-administration on an FR1 and PR schedule. Al-
though the number of amphetamine self-infusions varied as a func-
tion of dose, we found no evidence that individual differences in 
single-trial amphetamine CPP correlated with subsequent amphet-
amine self-administration rates under either the FR1 or PR sched-
ule. Thus, these results in rats challenge the idea that individual dif-
ferences in drug abuse vulnerability are related to the degree of 
reward derived from the fi rst drug experience. 
Finally, any conclusion based upon the present correlational 
results should be tempered because the CPP and self-administra-
tion paradigms are not equivalent measures of drug reward. While 
there seems to be reasonable correspondence between these para-
digms in their ability to identify drugs that have abuse liability (cf. 
Yokel 1987; Carr et al. 1989), both methodological and theoreti-
cal differences have tended to prevent direct comparison of results 
obtained with each paradigm. Recent evidence from monkeys in-
dicates that the relationship between CPP and self-administration 
is not completely concordant (Evans and Foltin 1997; Foltin and 
Evans 1997). Evidence also indicates that the neural mechanisms 
that underlie CPP and self-administration do not overlap complete-
ly (Bardo 1998). Thus, the failure to fi nd any relationship between 
single-trial amphetamine CPP and subsequent amphetamine self-
administration may be related to inherent differences between the 
paradigms, rather than to differences in the acute and chronic re-
warding effects of amphetamine. 
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